Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and Capecitabine Maintenance in Metastatic Colorectal Cancer
NCT03132025Phase 2Unknown
- Start
- Apr 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, single-blind trial of Rivoceranib in metastatic colorectal cancer (mCRC) (2 arms). Primary endpoint: Progression-Free Survival up to 10 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03132025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132025.